Literature DB >> 18538561

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

Hany Onsy Habashy1, Desmond G Powe, Emad A Rakha, Graham Ball, Claire Paish, Julia Gee, Robert I Nicholson, Ian O Ellis.   

Abstract

The forkhead-box A1 (FOXA1) controls downstream transcription of oestrogen receptor (ER)-regulated genes. In this study, the biological and prognostic value of FOXA1 expression was assessed immunohistochemically in a large and well-characterised series of invasive breast carcinoma with a long term follow-up using tissue microarray. FOXA1 expression was associated with steroid hormone receptors (ERalpha, PgR and AR), other variables of good prognosis such as smaller tumour size, lower histological grade, luminal cytokeratins (CK18 and CK7/8), BRCA1 and E-cadherin. Its expression showed an inverse relation with basal CKs (CK14 and CK5/6) and P-cadherin. We found an association between high FOXA1 expression and a better survival in the whole series however; multivariate analysis showed that FOXA1 was not an independent prognostic marker. In conclusion, our results show that FOXA1 protein is associated with markers of good prognosis supporting its role as a growth repressor in breast cancer. In this series, FOXA1 was found not to be of an independent prognostic significance in breast cancer and as such its immunohistochemical assessment alone does not appear to have relevance in routine practice to stratify ER-positive (luminal-like) tumours into clinically significant subgroups.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538561     DOI: 10.1016/j.ejca.2008.04.020

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  39 in total

1.  Subtype and pathway specific responses to anticancer compounds in breast cancer.

Authors:  Laura M Heiser; Anguraj Sadanandam; Wen-Lin Kuo; Stephen C Benz; Theodore C Goldstein; Sam Ng; William J Gibb; Nicholas J Wang; Safiyyah Ziyad; Frances Tong; Nora Bayani; Zhi Hu; Jessica I Billig; Andrea Dueregger; Sophia Lewis; Lakshmi Jakkula; James E Korkola; Steffen Durinck; François Pepin; Yinghui Guan; Elizabeth Purdom; Pierre Neuvial; Henrik Bengtsson; Kenneth W Wood; Peter G Smith; Lyubomir T Vassilev; Bryan T Hennessy; Joel Greshock; Kurtis E Bachman; Mary Ann Hardwicke; John W Park; Laurence J Marton; Denise M Wolf; Eric A Collisson; Richard M Neve; Gordon B Mills; Terence P Speed; Heidi S Feiler; Richard F Wooster; David Haussler; Joshua M Stuart; Joe W Gray; Paul T Spellman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-14       Impact factor: 11.205

2.  Foxa1 is essential for mammary duct formation.

Authors:  Yi Liu; Yongbing Zhao; Benjamin Skerry; Xiao Wang; Christelle Colin-Cassin; Derek C Radisky; Klaus H Kaestner; Zhaoyu Li
Journal:  Genesis       Date:  2016-03-29       Impact factor: 2.487

3.  Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.

Authors:  Nobuhiro Ijichi; Takashi Shigekawa; Kazuhiro Ikeda; Kuniko Horie-Inoue; Chikako Shimizu; Shigehira Saji; Kenjiro Aogi; Hitoshi Tsuda; Akihiko Osaki; Toshiaki Saeki; Satoshi Inoue
Journal:  Horm Cancer       Date:  2012-04-03       Impact factor: 3.869

4.  Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.

Authors:  Dorra BenAyed-Guerfali; Emna Dabbèche-Bouricha; Wajdi Ayadi; Fatma Trifa; Slim Charfi; Abdelmajid Khabir; Tahia Sellami-Boudawara; Raja Mokdad-Gargouri
Journal:  Mol Biol Rep       Date:  2019-04-02       Impact factor: 2.316

Review 5.  FOXA1: a transcription factor with parallel functions in development and cancer.

Authors:  Gina M Bernardo; Ruth A Keri
Journal:  Biosci Rep       Date:  2012-04-01       Impact factor: 3.840

6.  Epithelial ovarian cancer: An overview.

Authors:  Arpita Desai; Jingyao Xu; Kartik Aysola; Yunlong Qin; Chika Okoli; Ravipati Hariprasad; Ugorji Chinemerem; Candace Gates; Avinash Reddy; Omar Danner; Geary Franklin; Anachebe Ngozi; Guilherme Cantuaria; Karan Singh; William Grizzle; Charles Landen; Edward E Partridge; Valerie Montgomery Rice; E Shyam P Reddy; Veena N Rao
Journal:  World J Transl Med       Date:  2014-04-12

7.  FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer.

Authors:  Takashi Shigekawa; Nobuhiro Ijichi; Kazuhiro Ikeda; Kuniko Horie-Inoue; Chikako Shimizu; Shigehira Saji; Kenjiro Aogi; Hitoshi Tsuda; Akihiko Osaki; Toshiaki Saeki; Satoshi Inoue
Journal:  Horm Cancer       Date:  2011-10       Impact factor: 3.869

Review 8.  Fox transcription factors: from development to disease.

Authors:  Maria L Golson; Klaus H Kaestner
Journal:  Development       Date:  2016-12-15       Impact factor: 6.868

9.  Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification.

Authors:  Desmond G Powe; Gulfareen Akhtar; Hany Onsy Habashy; Tarek Abdel-Fatah; Emad A Rakha; Andrew R Green; Ian O Ellis
Journal:  Breast Cancer Res       Date:  2009-12-21       Impact factor: 6.466

10.  Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family.

Authors:  Sandeep Sanga; Bradley M Broom; Vittorio Cristini; Mary E Edgerton
Journal:  BMC Med Genomics       Date:  2009-09-11       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.